A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)

The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study.

Trial Summary

Age Range
≥12 years
Conditions the trial is for
COVID-19
What the trial is testing?
Bamlanivimab, Etesevimab, VIR-7831
Could I receive a Placebo?
Yes
Enrollment Goal
1755
Trial Dates
Oct 29, 2020 - Oct 18, 2021
How long will I be in the trial?
Participation could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the remainder of assessments performed in the home, local clinic, or by phone.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have mild to moderate COVID-19 illness: Fever, cough, sore throat, not feeling well, headache, muscle pain, digestive symptoms, shortness of breath when active, stuffy or runny nose, new loss of smell, chills

  • Participants must test positive for COVID-19 within three days before starting the study

Participants Must Not:

  • Participants must not be in the hospital

  • Participants must not need a machine to help them breathe (ventilator)

  • Participants must not be pregnant or breastfeeding

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.